In a move that signals a significant shift in the relationship between Big Pharma and the federal government, Johnson & Johnson (NYSE: JNJ) announced a [Read More…]
AstraZeneca has announced a landmark agreement with the US government to significantly cut the cost of prescription medicines for millions of American patients via the Most-Favored-Nation (MFN) drug pricing model. The deal includes up to 98% discounts on key respiratory drugs for direct patient purchases and a $50 billion commitment to US manufacturing and R&D, securing a three-year exemption from threatened tariffs.
AstraZeneca announced a record $4.5 billion investment in its new Virginia manufacturing facility. The expansion will create 3,600 jobs and bolster the production of life-saving medicines, including next-generation ADC cancer treatments and metabolic drugs.
Biotechnology giant Amgen is investing over $600 million to build a new research and development hub in Southern California. The cutting-edge facility will bring together top scientific minds to advance the creation of new medicines and is expected to generate hundreds of jobs, reinforcing the company’s commitment to U.S.-based innovation.
AstraZeneca has announced a landmark $50 billion investment in the United States through 2030, a strategic initiative designed to significantly enhance America’s leadership in pharmaceutical innovation.
More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.
